Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists

Research output: Contribution to journalComment/debatepeer-review

6 Scopus citations

Abstract

This commentary explores the complexities of the FIGO 2023 staging system and the inclusion of The Cancer Genome Atlas’s (TCGA) molecular classification in the management of endometrial cancer. It highlights the importance of histology as a prognostic tool, while scrutinizing the merits and demerits of its application to aggressive endometrial cancers. The commentary review sheds light on the recent introductions of lymphovascular space invasion (LVSI) and lymph node metastasis size in cancer staging. It outlines the difficulties in differentiating between synchronous and metastatic endometrial and ovarian cancers, underlining their implications on treatment strategies. Furthermore, the commentary discusses the integration of molecular classifications within the FIGO 2023 framework, emphasizing the pivotal yet challenging implementation of the pathogenic POLE mutation test. The commentary concludes by reaffirming the vital role of pathologists in executing the FIGO 2023 staging system.

Original languageEnglish (US)
Article number4101
JournalCancers
Volume15
Issue number16
DOIs
StatePublished - Aug 2023
Externally publishedYes

Keywords

  • FIGO staging
  • POLE mutations
  • TCGA-EC
  • endometrial cancer
  • molecular classification

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists'. Together they form a unique fingerprint.

Cite this